Publications & Reports

Overdose Deaths Involving Pharmaceutical Opioids in Washington State from 2010-2021.
Banta-Green C & Williams J.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington, November 2022.

Cognitive processing therapy or relapse prevention for comorbid posttraumatic stress disorder and alcohol use disorder: A randomized clinical trial. 
Simpson TL, Kaysen DL, Fleming CB, Rhew IC, Jaffe AE, Desai S, Hein DA, Berliner L, Donovan D, Resick PA.
PLOS One 2022 (in press).

Readiness of community pharmacies to implement an opioid safety intervention.
Floyd AS, Silcox J, Cousin E, Irwin AN, Gray M, Bolivar D, Bratberg J, Arnold J, Al-jammali Z, Hansen RN, Hartung DM, Green TC.
Journal of the American Pharmacies Association 2022 (in press).

Virtual training is more cost-effective than in-person training for preparing staff to implement contingency management.
Hartzler B, Hinde J, Land S, et al.
Journal of Technology in Behavioral Science 2022 (in press).

Cannabis-only use in the USA: Prevalence, demographics, use patterns, and health indicators.
Carlini BH, Schauer GL.
Journal of Cannabis Research 2022;4:39.

The Community-Based Medication-First program for opioid use disorder: A hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
Banta-Green CJ, Owens MD, Williams JR, Sears JM, Floyd AS, Williams-Gilbert W, Kingston S.
Addiction Science & Clinical Practice 2022;17:34.

A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients’ sexual risk behavior.
Hatch MA, Wells EA, Masters T, Beadnell B, Harwick R, Wright L, Peavy M, Ricardo-Bulis E, Wiest K, Shriver C, Baer, JS.
Journal of Substance Abuse Treatment 2022; 140:108826.

Care Navigation at Harm Reduction Programs: Community-Based “Meds First” Buprenorphine Program Preliminary Data.
Kingston S, Banta-Green C.
Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, June 2022.

Insights into a recovery community center model: Results from qualitative interviews with staff and member facilitators from Recovery Cafe in Seattle, Washington.
Owens MD, Banta-Green CJ, Newman A, Marren R, Takushi R.
Alcoholism Treatment Quarterly 2022 (in press).

Comparison of medical cannabis use reported on a confidential survey vs. documented in the electronic health record among primary care patients.
Lapham GT, Matson TE, Carrell DS . . . Schauer GL , et al.
JAMA Network Open 2022; 5(5):e2211677.

Simultaneous alcohol and marijuana use among young adults: A scoping review of prevalence, patterns, psychosocial correlates, and consequences.
Lee CM, Calhoun BH, Abdallah DA, Blayney JA, Schultz N, Brunner M, Patrick ME.
Alcohol Research: Current Reviews 2022;42(1).

Co-producing evidence-informed criminal legal re-entry policy with the community: An application of policy codesign.
Owens MD, Ngo S, Grinnell S, Pearlman D, Bekemeier B, Cusworth Walker S.
Evidence & Policy 2022;18(2):356-375.

Methadone: An Old Medication with Untapped Potential.
Peavy KM, Banta-Green C.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington, April 2022.

Retail cannabis environment and adolescent use: The role of advertising and retailers near home and school.
Firth CL, Carlini B, Dilley J, Guttmannova K, Hajat A.
Health and Place 2022; 75:102795.

Results from the 2021 WA State Syringe Service Program Health Survey.
Kingston S, Newman A, Banta-Green C, Glick S.
Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington, February 2022.

Distribution of Safer Drug Smoking Supplies as a Public Health Strategy.
Singh S, Banta-Green C, Kingston S.
Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, January 2022.

Perspectives on medication treatment for opioid use disorder in adolescents: Results from a provider learning series.
Peavy KM, Adwell A, Owens MD, Banta-Green CJ.
Substance Use & Misuse 2022 (in press).

Home cannabis cultivation in the United States and differences by state-level policy, 2019-2020.
Wadsworth E, Schauer GL, Hammond D.
American Journal on Drug and Alcohol Abuse 2022 (in press).

Cannabis legalization in Washington: Policy evolution and emerging evidence from the first nine years.
Dilley J, Firth C, Kilmer B.
IN: Pardal M (ed.). THE CANNABIS SOCIAL CLUB. Abingdon, UK: Routledge, 2023, pp. 155-186

Concentration of cannabis and tobacco retailers in Los Angeles County, California: A spatial analysis of potential effects on youth and ethnic minorities.
Rhee JU, Vieira VM, Firth CL, Pedersen ER, Dunbar MS, Timberlake DS.
Journal of Studies on Alcohol and Drugs 2022;83(4):502-511.

A trauma-informed parenting intervention model for mothers parenting young children during residential treatment for substance use disorder.
Jirkowic T, Graham CJ, Grant T.
Occupational Therapy in Mental Health 2022 (in press).

Behavioral healthcare organizations’ experiences related to use of telehealth as a result of the COVID-19 pandemic: an exploratory study.
Kisicki A, Becker S, Chaple M, Gustafson DH, Hartzler BJ, et al.
BMC Health Services Research 2022;22:775.

Discrimination, acculturative stress, alcohol use and their associations with alcohol-related consequences among Latino immigrant men.
Torres VN, Williams EC, Ceballos RM, Donovan DM, Ornealas IJ.
Journal of Ethnicity in Substance Abuse 2022 (in press).

Neighborhood social environment change in late adolescence predicts substance use in emerging adulthood.
Perez LG, Tucker JS, Pedersen ER, Troxel WM, Rodriguez A, Firth CL, Seelam R, Shih RA, D’Amico EJ.
Health & Place 2022;75:102807

Negative attitudes about medications for opioid use disorder among criminal legal staff.
Moore KE, Siebert SL, Kromash R, Owens MD, Allen D.
Drug and Alcohol Dependence Reports 2022;3:100056.

Self-reported medical and nonmedical cannabis use: Results from the 2018 Behavioral Risk Factor Surveillance System in 14 states.
Schauer GL, Roehler DR, Hoots BE.
Journal of Community Health 2022 (in press)

Study protocol for the Respond to Prevent Study: a multi-site randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC, Bratberg J, Irwin AN, Boggis J, Gray M, Leichtling G, … Floyd A, et al.
Substance Abuse 2022; 43(1):901-905.

Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19.
Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, Garner BR, Becker SJ. Journal of Substance Abuse Treatment 2022;132:108648.

Racial equity in cannabis policy: Diversity in the Massachusetts adult-use industry at 18-months.
Doonan SM, Johnson JK, Firth C, Flores A, Joshi S.
Cannabis 2022;5(1):30-41.

Prenatal alcohol exposure and mental health at midlife: A preliminary report on two longitudinal cohorts.
Coles CD, Grant TM, Kable JA, Stoner SA, Perez A, Collaborative Initiative on FASD.
Alcoholism: Clinical & Experimental Research 2022;46(2):232-242.

Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults.
Dunbar MS, Seelam R, Tucker JS, Firth CL, Pedersen ER, Klein DJ, Rodriguez A, D’Amico EJ.
Addictive Behaviors 2022;126: 107185